Details

Autor(en) / Beteiligte

• Shender, Victoria O.
• Anufrieva, Ksenia S.
• Shnaider, Polina V.
• Arapidi, Georgij P.
• Pavlyukov, Marat S.
• Ivanova, Olga M.
• Malyants, Irina K.
• Stepanov, Grigory A.
• Zhuravlev, Evgenii
• Ziganshin, Rustam H.
• Butenko, Ivan O.
• Bukato, Olga N.
• Klimina, Ksenia M.
• Veselovsky, Vladimir A.
• Grigorieva, Tatiana V.
• Malanin, Sergey Y.
• Aleshikova, Olga I.
• Slonov, Andrey V.
• Babaeva, Nataliya A.
• Ashrafyan, Lev A.
• Khomyakova, Elena
• Evtushenko, Evgeniy G.
• Lukina, Maria M.
• Wang, Zixiang
• Silantiev, Artemiy S.
• Nushtaeva, Anna A.
• Kharlampieva, Daria D.
• Lazarev, Vassili N.
• Lashkin, Arseniy I.
• Arzumanyan, Lorine K.
• Petrushanko, Irina Yu
• Makarov, Alexander A.
• Lebedeva, Olga S.
• Bogomazova, Alexandra N.
• Lagarkova, Maria A.
• Govorun, Vadim M.

Titel

Therapy-induced secretion of spliceosomal components mediates pro-survival crosstalk between ovarian cancer cells

Ist Teil von

• Nature communications, 2024-06, Vol.15 (1), p.5237-26, Article 5237

Ort / Verlag

London: Nature Publishing Group UK

Erscheinungsjahr

2024

Quelle

Electronic Journals Library

Beschreibungen/Notizen

• Ovarian cancer often develops resistance to conventional therapies, hampering their effectiveness. Here, using ex vivo paired ovarian cancer ascites obtained before and after chemotherapy and in vitro therapy-induced secretomes, we show that molecules secreted by ovarian cancer cells upon therapy promote cisplatin resistance and enhance DNA damage repair in recipient cancer cells. Even a short-term incubation of chemonaive ovarian cancer cells with therapy-induced secretomes induces changes resembling those that are observed in chemoresistant patient-derived tumor cells after long-term therapy. Using integrative omics techniques, we find that both ex vivo and in vitro therapy-induced secretomes are enriched with spliceosomal components, which relocalize from the nucleus to the cytoplasm and subsequently into the extracellular vesicles upon treatment. We demonstrate that these molecules substantially contribute to the phenotypic effects of therapy-induced secretomes. Thus, SNU13 and SYNCRIP spliceosomal proteins promote therapy resistance, while the exogenous U12 and U6atac snRNAs stimulate tumor growth. These findings demonstrate the significance of spliceosomal network perturbation during therapy and further highlight that extracellular signaling might be a key factor contributing to the emergence of ovarian cancer therapy resistance. Ovarian cancers frequently develop resistance to therapy. Here, using transcriptomics, proteomics, and preclinical models to analyse paired ascitic fluids before and after chemotherapy in ovarian cancer patients, the authors discover that extracellular secretion and spliceosomal components contribute to therapy resistance, enhancing the DNA damage response in recipient cancer cells.